Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Liao, H. X.
  • Lynch, R.
  • Zhou, T.
  • Gao, F.
  • Alam, S. M.
  • Boyd, S. D.
  • Fire, A. Z.
  • Roskin, K. M.
  • Schramm, C. A.
  • Zhang, Z.
  • Zhu, Jiang
  • Shapiro, L.
  • Mullikin, J. C.
  • Gnanakaran, S.
  • Hraber, P.
  • Wiehe, K.
  • Kelsoe, G.
  • Yang, G.
  • Xia, S. M.
  • Montefiori, D. C.
  • Parks, R.
  • Lloyd, K. E.
  • Scearce, R. M.
  • Soderberg, K. A.
  • Cohen, M.
  • Kamanga, G.
  • Louder, M. K.
  • Tran, L. M.
  • Chen, Y.
  • Cai, F.
  • Chen, S.
  • Moquin, S.
  • Du, X.
  • Joyce, M. G.
  • Srivatsan, S.
  • Zhang, B.
  • Zheng, A.
  • Shaw, G. M.
  • Hahn, B. H.
  • Kepler, T. B.
  • Korber, B. T. M.
  • Kwong, P. D.
  • Mascola, J. R.
  • Haynes, B. F.
  • NISC Comparative Sequencing Program

publication date

  • April 2013

journal

  • Nature  Journal

abstract

  • Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of HIV-1-infected individuals, and details of their generation could provide a blueprint for effective vaccination. Here we report the isolation, evolution and structure of a broadly neutralizing antibody from an African donor followed from the time of infection. The mature antibody, CH103, neutralized approximately 55% of HIV-1 isolates, and its co-crystal structure with the HIV-1 envelope protein gp120 revealed a new loop-based mechanism of CD4-binding-site recognition. Virus and antibody gene sequencing revealed concomitant virus evolution and antibody maturation. Notably, the unmutated common ancestor of the CH103 lineage avidly bound the transmitted/founder HIV-1 envelope glycoprotein, and evolution of antibody neutralization breadth was preceded by extensive viral diversification in and near the CH103 epitope. These data determine the viral and antibody evolution leading to induction of a lineage of HIV-1 broadly neutralizing antibodies, and provide insights into strategies to elicit similar antibodies by vaccination.

subject areas

  • AIDS Vaccines
  • Africa
  • Amino Acid Sequence
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antigens, CD4
  • Cell Lineage
  • Cells, Cultured
  • Clone Cells
  • Cross Reactions
  • Crystallography, X-Ray
  • Epitopes
  • Evolution, Molecular
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • HIV-1
  • Humans
  • Models, Molecular
  • Molecular Sequence Data
  • Mutation
  • Neutralization Tests
  • Phylogeny
  • Protein Structure, Tertiary
scroll to property group menus

Identity

PubMed Central ID

  • PMC3637846

International Standard Serial Number (ISSN)

  • 0028-0836

Digital Object Identifier (DOI)

  • 10.1038/nature12053

PubMed ID

  • 23552890
scroll to property group menus

Additional Document Info

start page

  • 469

end page

  • 476

volume

  • 496

issue

  • 7446

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support